Aarhus University Seal / Aarhus Universitets segl

Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms - Impact Of Comorbidity

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

DOI

  • Henrik Frederiksen
  • Szimonetta Szépligeti
  • Marie Bak, Department of Haematology, Zealand University Hospital, Roskilde, Denmark.
  • ,
  • Waleed Ghanima, Department of Haematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • ,
  • Hans Carl Hasselbalch, Department of Haematology, Zealand University Hospital, Roskilde, Denmark.
  • ,
  • Christian Fynbo Christiansen

Background: Patients with chronic myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are at high risk of vascular complications. However, the magnitude of this is risk not well known and the possible effect of comorbidity is poorly understood.

Aim: Our aim was to compare the risk of vascular diseases in patients with MPNs and matched comparisons from the general population and to study the effect modification of comorbidity.

Methods: We followed 3087 patients with ET, 6076 with PV, 3719 with PMF or unspecified MPN, and age- and sex-matched general population comparisons to estimate the risks of cardiovascular diseases such as myocardial infarction and stroke. We computed 5-year cumulative incidences (risks) for vascular disease in patients with MPNs and comparisons as well as 1-year and 5-year risks, risk differences, and hazard ratios (HRs) for vascular diseases comparing rates in each group of patients with their comparison cohort by level of comorbidity based on the Charlson Comorbidity Index (CCI) [score of 0 (low comorbidity), of 1-2 (moderate comorbidity), and of >2 (severe comorbidity)], as well as other comorbid conditions.

Results: The overall 5-year risk of vascular disease ranged from 0.5% to 7.7% in patients with MPNs, which was higher than the risk in the general population. In the same period, the adjusted HRs for vascular disease were 1.3 to 3.7 folds higher in patients with MPNs compared to the general population. An increase in CCI score was associated with an equally increased rate of most types of vascular diseases during the first 5 years of follow-up in both MPN and comparisons.

Conclusion: Patients with MPNs have a higher risk of vascular diseases during the first 5 years than that of the general population; however, comorbidity modifies the rates similarly in MPN and in the general population.

Original languageEnglish
JournalClinical epidemiology
Volume11
Pages (from-to)955-967
Number of pages13
ISSN1179-1349
DOIs
Publication statusPublished - 2019

    Research areas

  • Comorbidity, Epidemiology, Myeloproliferative neoplasms, Stroke, Thrombosis

See relations at Aarhus University Citationformats

ID: 173733412